According to the National Cancer Institute, about 40,710 people will be diagnosed with liver cancers in 2017, and approximately 28,920 will die of these diseases.
HCC is the most common form of liver cancer.
Stivarga is also approved to treat colorectal cancer and gastrointestinal stromal tumors when previous treatments are no longer effective.
The efficacy and safety of Stivarga for the treatment of HCC were studied in a randomized trial of 573 patients with HCC whose tumors had developed after receiving sorafenib.
Serious risks are associated with Stivarga, including liver damage, infections, hemorrhage, holes in the stomach or intestines, skin damage, hypertension, problems with blood flow to the heart, temporary brain swelling, and would healing complications.